Proteomics, genomics and transcriptomics: Their emerging roles in the discovery and validation of colorectal cancer biomarkers

Expert Review of Proteomics

Volumn 11, Issue 2, 2014, Pages 179-205

  Wang, Kui ^a,b   Huang, Canhua ^a   Nice, Edouard Collins ^b  

^a SICHUAN UNIVERSITY   (China)

^b MONASH UNIVERSITY   (Australia)

Author keywords

colorectal cancer; genomics; methylomics; miRNAomics; proteomics; transcriptomics

Indexed keywords

ADIPOPHILIN; ALPHA 1 ANTITRYPSIN; APC PROTEIN; B RAF KINASE; BIOLOGICAL MARKER; CADHERIN; CATHEPSIN D; COMPLEMENT COMPONENT C3; FIBRINOGEN; GLUTATHIONE TRANSFERASE P1; GROWTH DIFFERENTIATION FACTOR 15; HAPTOGLOBIN; HEAT SHOCK PROTEIN 27; HEMOGLOBIN A; HEMOGLOBIN BETA CHAIN; INTERFERON REGULATORY FACTOR 4; JUNCTIONAL ADHESION MOLECULE A; K RAS PROTEIN; LIPOCORTIN 2; LYSOZYME; MYELOBLASTIN; OCCLUDIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLAKOGLOBIN; PROTEIN P53; STOMATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN; MICRORNA; PROTEOME; TRANSCRIPTOME; TUMOR MARKER;

CELL INVASION; CELL MIGRATION; CHEMICAL LABELING; COLON CARCINOMA; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DNA METHYLATION; GENOMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; LIVER METASTASIS; LYMPH NODE METASTASIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; META ANALYSIS (TOPIC); MISMATCH REPAIR; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEOMICS; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TRANSCRIPTOMICS; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; ANTIBODY SPECIFICITY; BLOOD; CHEMISTRY; COLORECTAL NEOPLASMS; FECES; FEMALE; GENETIC ASSOCIATION; HIGH THROUGHPUT SCREENING; HUMAN GENOME; MALE; META ANALYSIS; METABOLISM; METHYLATION; PHYSIOLOGY; PLASMA; PROCEDURES; SERUM;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FECES; FEMALE; GENETIC ASSOCIATION STUDIES; GENOME, HUMAN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; METHYLATION; MICRORNAS; ORGAN SPECIFICITY; PLASMA; PROTEOME; SERUM; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84896974769     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.894466     Document Type: Review

References (220)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61(2):69-90
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1):11-30
3. Tjalsma H. Identification of biomarkers for colorectal cancer through proteomics-based approaches. Expert Rev Proteomics 2010; 7(6):879-95
4. Pawa N, Arulampalam T, Norton JD. Screening for colorectal cancer: established and emerging modalities. Nat Rev Gastroenterol Hepatol 2011;8(12):711-22
5. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet 2010;375(9719): 1030-47
6. Lieberman D. Progress and challenges in colorectal cancer screening and surveillance. Gastroenterology 2010;138(6):2115-26
7. Lin JS, Webber EM, Beil TL, et al. Fecal DNA testing in screening for colorectal cancer in average-risk adults [Internet]. Agency for Healthcare Research and Quality (US), Rockville, MD, USA; 2012; (Comparative Effectiveness Reviews, No. 52.) Available from: www.ncbi.nlm.nih.gov/ books/NBK91369/
8. de Wit M, Fijneman RJ, Verheul HM, et al. Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. Clin Biochem 2013;46(6):466-79
9. Baron JA. Screening for cancer with molecular markers: progress comes with potential problems. Nat Rev Cancer 2012; 12(5):368-71
10. Midgley RS, Church D, Kerr DJ. The emergence of 'omics for the management of colorectal cancer. Curr Opin Oncol 2011; 23(4):410-14
11. Van Schaeybroeck S, Allen WL, Turkington RC, Johnston PG. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol 2011;8(4):222-32
12. Mallick P, Kuster B. Proteomics: a pragmatic perspective. Nat Biotechnol 2010;28(7):695-709
13. Ikonomou G, Samiotaki M, Panayotou G. Proteomic methodologies and their application in colorectal cancer research. Crit Rev Clin Lab Sci 2009;46(5-6):319-42
14. Bensimon A, Heck AJ, Aebersold R. Mass spectrometry-based proteomics and network biology. Annu Rev Biochem 2012;81: 379-405
15. Angel TE, Aryal UK, Hengel SM, et al. Mass spectrometry-based proteomics: existing capabilities and future directions. Chem Soc Rev 2012;41(10):3912-28
16. Zhang Y, Fonslow BR, Shan B, et al. Protein analysis by shotgun/bottom-up proteomics. Chem Rev 2013;113(4):2343-94
17. Liu R, Wang K, Yuan K, et al. Integrative oncoproteomics strategies for anticancer drug discovery. Expert Rev Proteomics 2010;7(3):411-29
18. Megger DA, Bracht T, Meyer HE, Sitek B. Label-free quantification in clinical proteomics. Biochim Biophys Acta 2013; 1834(8):1581-90
19. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997;18(11):2071-7
20. Alban A, David SO, Bjorkesten L, et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003; 3(1):36-44
21. Timms JF, Cramer R. Difference gel electrophoresis. Proteomics 2008;8(23(24): 4886-97
22. Pham TV, Piersma SR, Oudgenoeg G, Jimenez CR. Label-free mass spectrometry-based proteomics for biomarker discovery and validation. Expert Rev Mol Diagn 2012;12(4):343-59
23. Patel VJ, Thalassinos K, Slade SE, et al. A comparison of labeling and label-free mass spectrometry-based proteomics approaches. J Proteome Res 2009;8(7):3752-9
24. Cornett DS, Reyzer ML, Chaurand P, Caprioli RM. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nat Methods 2007; 4(10):828-33
25. Ait-Belkacem R, Sellami L, Villard C, et al. Mass spectrometry imaging is moving toward drug protein co-localization. Trends Biotechnol 2012;30(9):466-74
26. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics 2012;11(6):O111.016717
27. Yin HR, Zhang L, Xie LQ, et al. Hyperplex-MRM: a hybrid multiple reaction monitoring method using mTRAQ/iTRAQ labeling for multiplex absolute quantification of human colorectal cancer biomarker. J Proteome Res 2013; 12(9):3912-19
28. Jimenez CR, Knol JC, Meijer GA, Fijneman RJ. Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J Proteomics 2010; 73(10):1873-95
29. Lei Y, Huang K, Gao C, et al. Proteomics identification of ITGB3 as a key regulator in reactive oxygen species-induced migration and invasion of colorectal cancer cells. Mol Cell Proteomics 2011;10(10):M110.005397
30. Luque-Garcia JL, Martinez-Torrecuadrada JL, Epifano C, et al. Differential protein expression on the cell surface of colorectal cancer cells associated to tumor metastasis. Proteomics 2010;10(5):940-52
31. de Wit M, Jimenez CR, Carvalho B, et al. Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut 2012;61(6):855-64
32. Xue H, Lu B, Lai M. The cancer secretome: a reservoir of biomarkers. J Transl Med 2008;6:52
33. Xue H, Lu B, Zhang J, et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res 2010;9(1):545-55
34. Barderas R, Mendes M, Torres S, et al. In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion. Mol Cell Proteomics 2013;12(6): 1602-20
35. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 2009;6(3):267-83
36. Ji H, Greening DW, Barnes TW, et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics 2013;13(10-11):1672-86
37. Volmer MW, Stuhler K, Zapatka M, et al. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 2005;5(10): 2587-601
38. Wang P, Lo A, Young JB, et al. Targeted quantitative mass spectrometric identification of differentially expressed proteins between Bax-expressing and deficient colorectal carcinoma cells. J Proteome Res 2009;8(7): 3403-14
39. Leroy C, Fialin C, Sirvent A, et al. Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. Cancer Res 2009;69(6):2279-86
40. Tan HT, Tan S, Lin Q, et al. Quantitative and temporal proteome analysis of butyrate-treated colorectal cancer cells. Mol Cell Proteomics 2008;7(6):1174-85
41. Fung KY, Lewanowitsch T, Henderson ST, et al. Proteomic analysis of butyrate effects and loss of butyrate sensitivity in HT29 colorectal cancer cells. J Proteome Res 2009;8(3):1220-7
42. Bauer KM, Lambert PA, Hummon AB. Comparative label-free LC-MS/MS analysis of colorectal adenocarcinoma and metastatic cells treated with 5-fluorouracil. Proteomics 2012;12(12):1928-37
43. Torres S, Bartolome RA, Mendes M, et al. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res 2013; 19(21):6006-19
44. Xie LQ, Zhao C, Cai SJ, et al. Novel proteomic strategy reveal combined alpha1 antitrypsin and cathepsin D as biomarkers for colorectal cancer early screening. J Proteome Res 2010;9(9):4701-9
45. Han CL, Chen JS, Chan EC, et al. An informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer. Mol Cell Proteomics 2011;10(4):M110.003087
46. Pei H, Zhu H, Zeng S, et al. Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J Proteome Res 2007;6(7):2495-501
47. Meding S, Balluff B, Elsner M, et al. Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J Pathol 2012;228:459-70
48. Chang HJ, Lee MR, Hong SH, et al. Identification of mitochondrial FoF1-ATP synthase involved in liver metastasis of colorectal cancer. Cancer Sci 2007;98(8): 1184-91
49. Martinez-Aguilar J, Chik J, Nicholson J, et al. Quantitative mass spectrometry for colorectal cancer proteomics. Proteomics Clin Appl 2013;7(1(2):42-54
50. Ma Y, Peng J, Huang L, et al. Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach. Electrophoresis 2009;30(15):2591-9
51. Matsubara J, Honda K, Ono M, et al. Identification of adipophilin as a potential plasma biomarker for colorectal cancer using label-free quantitative mass spectrometry and protein microarray. Cancer Epidemiol Biomarkers Prev 2011;20(10):2195-203
52. Ji D, Li M, Zhan T, et al. Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients. Carcinogenesis 2013;34(6):1265-72
53. Tsai MH, Wu CC, Peng PH, et al. Identification of secretory gelsolin as a plasma biomarker associated with distant organ metastasis of colorectal cancer. J Mol Med (Berl) 2012;90(2):187-200
54. Choi JW, Liu H, Shin DH, et al. Proteomic and cytokine plasma biomarkers for predicting progression from colorectal adenoma to carcinoma in human patients. Proteomics 2013;13(15):2361-74
55. Ang CS, Rothacker J, Patsiouras H, et al. Murine fecal proteomics: a model system for the detection of potential biomarkers for colorectal cancer. J Chromatogr A 2010; 1217(19):3330-40
56. Ang CS, Nice EC. Targeted in-gel MRM: a hypothesis driven approach for colorectal cancer biomarker discovery in human feces. J Proteome Res 2010;9(9):4346-55
57. Ang CS, Rothacker J, Patsiouras H, et al. Use of multiple reaction monitoring for multiplex analysis of colorectal cancer-associated proteins in human feces. Electrophoresis 2011;32(15):1926-38
58. Tong Y, Yang W, Koeffler HP. Mouse models of colorectal cancer. Chin J Cancer 2011;30(7):450-62
59. Hung KE, Maricevich MA, Richard LG, et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci USA 2010;107(4):1565-70
60. Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009;459(7244):262-5
61. Witze ES, Old WM, Resing KA, Ahn NG. Mapping protein post-translational modifications with mass spectrometry. Nat Methods 2007;4(10):798-806
62. Deribe YL, Pawson T, Dikic I. Posttranslational modifications in signal integration. Nat Struct Mol Biol 2010; 17(6):666-72
63. Ito S, Hayama K, Hirabayashi J. Enrichment strategies for glycopeptides. Methods Mol Biol 2009;534:195-203
64. Rush J, Moritz A, Lee KA, et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 2005;23(1):94-101
65. Ficarro SB, Adelmant G, Tomar MN, et al. Magnetic bead processor for rapid evaluation and optimization of parameters for phosphopeptide enrichment. Anal Chem 2009;81(11):4566-75
66. Kim W, Bennett EJ, Huttlin EL, et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 2011;44(2):325-40
67. Kim SC, Sprung R, Chen Y, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 2006;23(4):607-18
68. Leichert LI, Gehrke F, Gudiseva HV, et al. Quantifying changes in the thiol redox proteome upon oxidative stress in vivo. Proc Natl Acad Sci USA 2008;105(24):8197-202
69. Seo YH, Carroll KS. Profiling protein thiol oxidation in tumor cells using sulfenic acid-specific antibodies. Proc Natl Acad Sci USA 2009;106(38):16163-8
70. Yusuf MA, Chuang T et al. Cys-141 glutathionylation of human p53: studies using specific polyclonal antibodies in cancer samples and cell lines. Free Radic Biol Med 2010;49(5):908-17
71. Ahn YH, Kim KH, Shin PM, et al. Identification of low-abundance cancer biomarker candidate TIMP1 from serum with lectin fractionation and peptide affinity enrichment by ultrahigh-resolution mass spectrometry. Anal Chem 2012;84(3):1425-31
72. Organ SL, Tong J, Taylor P, et al. Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer. J Proteome Res 2011;10(7):3200-11
73. Calligaris D, Villard C, Lafitte D. Advances in top-down proteomics for disease biomarker discovery. J Proteomics 2011;74(7):920-34
74. Zhou H, Ning Z, Starr AE, et al. Advancements in top-down proteomics. Anal Chem 2012;84(2):720-34
75. Mertins P, Qiao JW, Patel J, et al. Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 2013;10(7):634-7
76. Siuti N, Kelleher NL. Decoding protein modifications using top-down mass spectrometry. Nat Methods 2007;4(10): 817-21
77. Zhang H, Ge Y. Comprehensive analysis of protein modifications by top-down mass spectrometry. Circ Cardiovasc Genet 2011; 4(6):711
78. Tran JC, Zamdborg L, Ahlf DR, et al. Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature 2011;480(7376):254-8
79. Catherman AD, Durbin KR, Ahlf DR, et al. Large-scale top down proteomics of the human proteome: membrane proteins, mitochondria, and senescence. Mol Cell Proteomics 2013;12(12):3465-73
80. Zheng Q, Wang XJ. GOEAST: a web-based software toolkit for Gene Ontology enrichment analysis. Nucleic Acids Res 2008; 36(Web Server issue):W358-63
81. Szklarczyk D, Franceschini A, Kuhn M, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011;39(Database issue):D561-8
82. Cline MS, Smoot M, Cerami E, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2007;2(10):2366-82
83. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5):646-74
84. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008;135(4): 1079-99
85. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011;6:479-507
86. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61(5):759-67
87. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314(5797):268-74
88. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318(5853): 1108-13
89. Bass AJ, Lawrence MS, Brace LE, et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet 2011; 43(10):964-8
90. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009; 361(25):2449-60
91. Schweiger MR, Hussong M, Rohr C, Lehrach H. Genomics and epigenomics of colorectal cancer. Wiley Interdiscip Rev Syst Biol Med 2013;5(2):205-19
92. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011;8(12):686-700
93. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301(5895):89-92
94. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010;29(1):181-206
95. Hammoud SS, Cairns BR, Jones DA. Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol 2013;25(2):177-83
96. Schuebel KE, Chen W, Cope L, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007;3(9):1709-23
97. Fukutomi S, Seki N, Koda K, Miyazaki M. Identification of methylation-silenced genes in colorectal cancer cell lines: genomic screening using oligonucleotide arrays. Scand J Gastroenterol 2007;42(12):1486-94
98. Khamas A, Ishikawa T, Mogushi K, et al. Genome-wide screening for methylation-silenced genes in colorectal cancer. Int J Oncol 2012;41(2):490-6
99. Kibriya MG, Raza M, Jasmine F, et al. A genome-wide DNA methylation study in colorectal carcinoma. BMC Med Genomics 2011;4:50
100. Kim YH, Lee HC, Kim SY, et al. Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann Surg Oncol 2011;18(8):2338-47
101. Oster B, Thorsen K, Lamy P, et al. Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer 2011;129(12):2855-66
102. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6(2):107-16
103. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009;41(2):178-86
104. Naumov VA, Generozov EV, Zaharjevskaya NB, et al. Genome-scale analysis of DNA methylation in colorectal cancer using Infinium HumanMethylation450 BeadChips. Epigenetics 2013;8(9):921-34
105. Simmer F, Brinkman AB, Assenov Y, et al. Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues. Epigenetics 2012;7(12):1355-67
106. Beggs AD, Jones A, El-Bahwary M, et al. Whole-genome methylation analysis of benign and malignant colorectal tumours. J Pathol 2013;229(5):697-704
107. Zou HZ, Yu BM, Wang ZW, et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res 2002;8(1):188-91
108. Wallner M, Herbst A, Behrens A, et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res 2006;12(24): 7347-52
109. Nishio M, Sakakura C, Nagata T, et al. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker. Anticancer Res 2010; 30(7):2673-82
110. Lee BB, Lee EJ, Jung EH, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 2009;15(19):6185-91
111. Church TR, Wandell M, Lofton-Day C, et al. PRESEPT Clinical Study Steering Committee, Investigators and Study Team. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014;63(2):317-25
112. Warren JD, Xiong W, Bunker AM, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med 2011;9:133
113. Lange CP, Campan M, Hinoue T, et al. Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS One 2012;7(11):e50266
114. Muller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004;363(9417):1283-5
115. Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005;97(15):1124-32
116. Nagasaka T, Tanaka N, Cullings HM, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst 2009;101(18):1244-58
117. Glockner SC, Dhir M, Yi JM, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009;69(11):4691-9
118. Cassinotti E, Melson J, Liggett T, et al. DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer 2012;131(5):1153-7
119. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009;10(1):57-63
120. Habermann JK, Bader FG, Franke C, et al. From the genome to the proteome - biomarkers in colorectal cancer. Langenbecks Arch Surg 2008;393(1):93-104
121. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487(7407):330-7
122. Marisa L, de Reynies A, Duval A, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 2013;10(5):e1001453
123. Morozova O, Hirst M, Marra MA. Applications of new sequencing technologies for transcriptome analysis. Annu Rev Genomics Hum Genet 2009;10:135-51
124. Wu Y, Wang X, Wu F, et al. Transcriptome profiling of the cancer, adjacent non-tumor and distant normal tissues from a colorectal cancer patient by deep sequencing. PLoS One 2012;7(8): e41001
125. Han SW, Kim HP, Shin JY, et al. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS One 2013;8(5):e64271
126. Slaby O, Svoboda M, Michalek J, Vyzula R . MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009;8:102
127. Cho WC. Great potential of miRNAs as predictive and prognostic markers for cancer. Expert Rev Mol Diagn 2012;12(4): 315-18
128. Wu WK, Law PT, Lee CW, et al. MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis 2011; 32(3):247-53
129. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435(7043): 834-8
130. Cummins JM, He Y, Leary RJ, et al. The colorectal microRNAome. Proc Natl Acad Sci USA 2006;103(10):3687-92
131. Motoyama K, Inoue H, Takatsuno Y, et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 2009; 34(4):1069-75
132. Li X, Zhang G, Luo F, et al. Identification of aberrantly expressed miRNAs in rectal cancer. Oncol Rep 2012;28(1):77-84
133. Gaedcke J, Grade M, Camps J, et al. The rectal cancer microRNAome - microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res 2012;18(18):4919-30
134. Hamfjord J, Stangeland AM, Hughes T, et al. Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS One 2012;7(4):e34150
135. Schee K, Lorenz S, Worren MM, et al. Deep sequencing the MicroRNA transcriptome in colorectal cancer. PLoS One 2013;8(6):e66165
136. Schepeler T, Reinert JT, Ostenfeld MS, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008; 68(15):6416-24
137. Vega AB, Pericay C, Moya I, et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep 2013;30(1):320-6
138. Arndt GM, Dossey L, Cullen LM, et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009;9:374
139. Lanza G, Ferracin M, Gafa R, et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer 2007;6:54
140. Sarver AL, French AJ, Borralho PM, et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 2009;9:401
141. Slattery ML, Wolff E, Hoffman MD, et al. MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer 2011;50(3):196-206
142. Balaguer F, Moreira L, Lozano JJ, et al. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin Cancer Res 2011;17(19):6239-49
143. Bartley AN, Yao H, Barkoh BA, et al. Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer. Clin Cancer Res 2011;17(23):7283-93
144. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127(1):118-26
145. Toiyama Y, Takahashi M, Hur K, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 2013;105(12):849-59
146. Wu CW, Ng SS, Dong YJ, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 2012;61(5):739-45
147. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58(10):1375-81
148. Hofsli E Sjursen W, et al. Identification of serum microRNA profiles in colon cancer. Br J Cancer 2013;108(8):1712-19
149. Kanaan Z, Roberts H, Eichenberger MR, et al. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg 2013;258(3):400-8
150. Link A, Balaguer F, Shen Y, et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010;19(7):1766-74
151. Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, et al. Differential expression of miR-144 as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol 2011;46(12):1391-402
152. Ahmed FE, Ahmed NC, Vos PW, et al. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genomics Proteomics 2013;10(3):93-113
153. Hood LE, Omenn GS, Moritz RL, et al. New and improved proteomics technologies for understanding complex biological systems: addressing a grand challenge in the life sciences. Proteomics 2012;12(18):2773-83
154. Paik YK, Hancock WS. Uniting ENCODE with genome-wide proteomics. Nat Biotechnol 2012;30(11):1065-7
155. Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 2012;13(4):227-32
156. Meierhofer D, Weidner C, Hartmann L, et al. Protein sets define disease states and predict in vivo effects of drug treatment. Mol Cell Proteomics 2013;12(7):1965-79
157. Garg G, Ranganathan S. In silico secretome analysis approach for next generation sequencing transcriptomic data. BMC Genomics 2011;12(Suppl 3):S14
158. ENCODE Project Consortium. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011;9(4): e1001046
159. Bernstein BE, Birney E, Dunham I, et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489(7414):57-74
160. Goode RJ, Yu S, Kannan A, et al. The proteome browser web portal. J Proteome Res 2013;12(1):172-8
161. Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010;7(5):251-65
162. The Protein Atlas. Available from: www. proteinatlas.org
163. Antibodypedia. Available from: www. antibodypedia.com/
164. BioRag. Available from: www.biorag.org
165. Tan HT, Wu W, Ng YZ, et al. Proteomic analysis of colorectal cancer metastasis: stathmin-1 revealed as a player in cancer cell migration and prognostic marker. J Proteome Res 2012;11(2):1433-45
166. Ghosh D, Yu H, Tan XF, et al. Identification of key players for colorectal cancer metastasis by iTRAQ quantitative proteomics profiling of isogenic SW480 and SW620 cell lines. J Proteome Res 2011; 10(10):4373-87
167. Gouyer V, Fontaine D, Dumont P, et al. Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells. Oncogene 2008;27(29):4024-33
168. Wu CC, Chen HC, Chen SJ, et al. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 2008;8(2):316-32
169. Zhao L, Liu L, Wang S, et al. Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. J Cancer Res Clin Oncol 2007; 133(10):771-82
170. Snoeren N, Emmink BL, Koerkamp MJ, et al. Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer. Br J Cancer 2013;109(6): 1636-47
171. Mu Y, Chen Y, Zhang G, et al. Identification of stromal differentially expressed proteins in the colon carcinoma by quantitative proteomics. Electrophoresis 2013;34(11):1679-92
172. Zhou R, Huang W, Yao Y, et al. CA II, a potential biomarker by proteomic analysis, exerts significant inhibitory effect on the growth of colorectal cancer cells. Int J Oncol 2013;43(2):611-21
173. Zougman A, Hutchins GG, Cairns DA, et al. Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker. Eur J Cancer 2013;49(2):531-9
174. Peng Y, Li X, Wu M, et al. New prognosis biomarkers identified by dynamic proteomic analysis of colorectal cancer. Mol Biosyst 2012;8(11):3077-88
175. Sugihara Y, Taniguchi H, Kushima R, et al. Proteomic-based identification of the APC-binding protein EB1 as a candidate of novel tissue biomarker and therapeutic target for colorectal cancer. J Proteomics 2012;75(17):5342-55
176. Kim CY, Jung WY, Lee HJ, et al. Proteomic analysis reveals overexpression of moesin and cytokeratin 17 proteins in colorectal carcinoma. Oncol Rep 2012; 27(3):608-20
177. O'Dwyer D, Ralton LD, O'Shea A, Murray GI. The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS One 2011; 6(11):e27718
178. Besson D, Pavageau AH, Valo I, et al. A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker. Mol Cell Proteomics 2011; 10(12):M111.009712
179. Alvarez-Chaver P, Rodriguez-Pineiro AM, Rodriguez-Berrocal FJ, et al. Selection of putative colorectal cancer markers by applying PCA on the soluble proteome of tumors: NDK A as a promising candidate. J Proteomics 2011;74(6):874-86
180. Huang LY, Xu Y, Cai GX, et al. S100A4 over-expression underlies lymph node metastasis and poor prognosis in colorectal cancer. World J Gastroenterol 2011;17(1):69-78
181. Luo YX, Cui J, Wang L, et al. Identification of cancer-associated proteins by proteomics and downregulation of beta-tropomyosin expression in colorectal adenoma and cancer. Proteomics Clin Appl 2009;3(12):1397-406
182. He ZY, Wen H, Shi CB, Wang J. Up-regulation of hnRNP A1, Ezrin, tubulin beta-2C and Annexin A1 in sentinel lymph nodes of colorectal cancer. World J Gastroenterol 2010;16(37):4670-6
183. Zhao L, Wang H, Sun X, Ding Y. Comparative proteomic analysis identifies proteins associated with the development and progression of colorectal carcinoma. FEBS J 2010;277(20):4195-204
184. Zhao L, Wang H, Liu C, et al. Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1. Gut 2010;59(9):1226-35
185. Chen D, Chen F, Lu X, et al. Identification of prohibitin as a potential biomarker for colorectal carcinoma based on proteomics technology. Int J Oncol 2010;37(2):355-65
186. Ma Y, Zhao M, Zhong J, et al. Proteomic profiling of proteins associated with lymph node metastasis in colorectal cancer. J Cell Biochem 2010;110(6):1512-19
187. Zhang Y, Ye Y, Shen D, et al. Identification of transgelin-2 as a biomarker of colorectal cancer by laser capture microdissection and quantitative proteome analysis. Cancer Sci 2010;101(2):523-9
188. Lin Y, Buckhaults PJ, Lee JR, et al. Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer. Neoplasia 2009; 11(9):864-73
189. Liu W, Ma Y, Huang L, et al. Identification of HSP27 as a potential tumor marker for colorectal cancer by the two-dimensional polyacrylamide gel electrophoresis. Mol Biol Rep 2010;37(7):3207-16
190. Yue F, Wang LS, Xia L, et al. Modulated T-complex protein 1 zeta and peptidyl-prolyl cis-trans isomerase B are two novel indicators for evaluating lymph node metastasis in colorectal cancer: evidence from proteomics and bioinformatics. Proteomics Clin Appl 2009;3(10):1225-35
191. Ma YL, Peng JY, Zhang P, et al. Heterogeneous nuclear ribonucleoprotein A1 is identified as a potential biomarker for colorectal cancer based on differential proteomics technology. J Proteome Res 2009;8(10):4525-35
192. Ma Y, Peng J, Liu W, et al. Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol Cell Proteomics 2009;8(8):1878-90
193. Alfonso P, Canamero M, Fernandez-Carbonie F, et al. Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J Proteome Res 2008;7(10):4247-55
194. Zhao L, Wang H, Li J, et al. Overexpression of Rho GDP-dissociation inhibitor alpha is associated with tumor progression and poor prognosis of colorectal cancer. J Proteome Res 2008;7(9):3994-4003
195. Rho JH, Qin S, Wang JY, Roehrl MH. Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J Proteome Res 2008;7(7):2959-72
196. Watanabe M, Takemasa I, Kawaguchi N, et al. An application of the 2-nitrobenzenesulfenyl method to proteomic profiling of human colorectal carcinoma: a novel approach for biomarker discovery. Proteomics Clin Appl 2008;2(6):925-35
197. Thierolf M, Hagmann ML, Pfeffer M, et al. Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100A12 as potential cancer biomarker. Proteomics Clin Appl 2008;2(1):11-22
198. Wang Y, Ma Y, Lu B, et al. Differential expression of mimecan and thioredoxin domain-containing protein 5 in colorectal adenoma and cancer: a proteomic study. Exp Biol Med (Maywood) 2007;232(9):1152-9
199. Coghlin C, Carpenter B, Dundas SR, et al. Characterization and over-expression of chaperonin t-complex proteins in colorectal cancer. J Pathol 2006;210(3):351-7
200. Carpenter B, McKay M, Dundas SR, et al. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer 2006;95(7):921-7
201. Roessler M, Rollinger W, Mantovani-Endl L, et al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cell Proteomics 2006;5(11):2092-101
202. Kim H, Kang HJ, You KT, et al. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 2006;6(11):3466-76
203. Xing X, Lai M, Gartner W, et al. Identification of differentially expressed proteins in colorectal cancer by proteomics: down-regulation of secretagogin. Proteomics 2006;6(9):2916-23
204. Roessler M, Rollinger W, Palme S, et al. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res 2005;11(18):6550-7
205. Lawrie LC, Dundas SR, Curran S, Murray GI. Liver fatty acid binding protein expression in colorectal neoplasia. Br J Cancer 2004;90(10):1955-60
206. Zhang X, Xiao Z, Liu X, et al. The potential role of ORM2 in the development of colorectal cancer. PLoS One 2012;7(2):e31868
207. Ahn YH, Lee JY, Kim YS, et al. Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. J Proteome Res 2009;8(9):4216-24
208. Murakoshi Y, Honda K, Sasazuki S, et al. Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci 2011;102(3):630-8
209. Zhao L, Liu Y, Sun X, et al. Serum proteome analysis for profiling protein markers associated with lymph node metastasis in colorectal carcinoma. J Comp Pathol 2011;144(2-3):187-94
210. Helgason HH, Engwegen JY, Zapatka M, et al. Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry. Oncol Rep 2010;24(1):57-64
211. Rodriguez-Pineiro AM, de la Cadena MP, Lopez-Saco A, et al. Differential expression of serum clusterin isoforms in colorectal cancer. Mol Cell Proteomics 2006;5(9):1647-57
212. Ang PW, Loh M, Liem N, et al. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer 2010;10:227
213. Yagi K, Akagi K, Hayashi H, et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 2010; 16(1):21-33
214. Spisak S, Kalmar A, Galamb O, et al. Genome-wide screening of genes regulated by DNA methylation in colon cancer development. PLoS One 2012;7(10):e46215
215. Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012;22(2):271-82
216. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103(7):2257-61
217. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299(4):425-36
218. Wang Q, Huang Z, Ni S, et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One 2012;7(9):e44398
219. Luo X, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma MicroRNAs for early detection of colorectal cancer. PLoS One 2013;8(5):e62880
220. Giraldez MD, Lozano JJ, Ramirez G, et al. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastroenterol Hepatol 2013;11(6):681-8.e683